{"disease":{"id":"relapsed-refractory-rheumatic-and-immunologic-disease-associated-haemophagocytic-lymphohistiocytosis","name":"relapsed refractory rheumatic and immunologic disease associated haemophagocytic lymphohistiocytosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07208058","title":"A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}